Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

• Status: Completed
• Trial end date: 2021-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Centre de Recherche sur les Filarioses et autres Maladies Tropicales (CRFilMT)
• Treatments: Ivermectin

Criteria

Inclusion Criteria:

• Loa loa blood microfilariae of between 5,000 - 18,000 per mL

Exclusion Criteria:

• known allergy to ivermectin; severe comorbidities